Biotech Values

[Biopharm investor]

In addition to Norvasc, about a year after the product was first genericized, Greenstone continues to have the leading 54 share (among 19 generic competitors) in the generic Zoloft (sertraline) market.

What was really interesting in the case of generic Zoloft, the launch of sertraline was actually led by Greenstone, whereas in the case of Norvasc, I think Mylan opened the market and Greenstone quickly followed.

96% of the Zoloft market has converted to generics and the price of sertraline is about 1%, if that, of the brand WAC of Zoloft.